1. The University of Texas System (48 from 5,450 patents)

2. Merck Sharp + Dohme Corp. (16 from 2,405 patents)

3. Chempartner Corporation (7 from 7 patents)

4. Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa (5 from 47 patents)

5. Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a. (3 from 11 patents)

6. Navire Pharma, Inc. (3 from 3 patents)

7. Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l. (2 from 4 patents)

8. Golgi Neurosciences S.r.l. (2 from 3 patents)

9. Addex Pharma, S.a. (1 from 37 patents)

10. Axxam S.p.a. (1 from 6 patents)

11. Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l. (1 from 1 patent)

12. Istituto De Ricerche Di Biologia Molecolare P. Angeletti Spa. (1 from 1 patent)

13. Msd Italia S.r.l. (7 patents)

1. 12258337 - Bicyclic CX3CR1 receptor agonists

2. 12252480 - Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

3. 12186324 - Imidazopiperazine inhibitors of transcription activating proteins

4. 12036231 - Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

5. 11958839 - Bicyclic CX3CR1 receptor agonists

6. 11958849 - GLS1 inhibitors for treating disease

7. 11945815 - PTPN11 inhibitors

8. 11932643 - Substituted heterocyclic inhibitors of PTPN11

9. 11840536 - Heterocyclic inhibitors of PTPN11

10. 11725008 - Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

11. 11713313 - GLS1 inhibitors for treating disease

12. 11603365 - Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

13. 11560366 - Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

14. 11466017 - Heterocyclic inhibitors of PTPN11

15. 11434233 - Heterocyclic inhibitors of ATR kinase